Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026092 | 1.00 | L3MBTL3 (0.32) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| Methyl Alcohol SCHEMBL29281740 | 0.95 | KDM4E (0.31) | L3MBTL3L3MBTL1KDM4ETDP1 | |
| SCHEMBL157634 | 0.91 | KDM4E (0.34) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| SCHEMBL157635 | 0.91 | KDM4E (0.34) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| Bromide SCHEMBL29250447 | 0.90 | KDM4E (0.33) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| SCHEMBL28479441 | 0.90 | KDM4E (0.33) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| Hydrochloric Acid SCHEMBL28987758 | 0.90 | KDM4E (0.33) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| SCHEMBL21192477 | 0.89 | SLC18A3 (0.38) | L3MBTL3L3MBTL1KDM4E | |
| Methyl Alcohol SCHEMBL28586250 | 0.87 | KDM4E (0.35) | L3MBTL3L3MBTL1KDM4ETDP1MBTD1 | |
| Methylene Chloride SCHEMBL29129857 | 0.86 | KDM4E (0.34) | L3MBTL3L3MBTL1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315710-B | Method for preparing or purifying regorafenib | 江苏豪森药业集团有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-114315710-A | Method for preparing or purifying regorafenib | 江苏豪森药业集团有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-113880883-A | Nucleoside phosphate prodrug preparation method | 奥锐特药业股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-107955333-B | Reinforced and toughened epoxy resin composition | 江南大学 | 2019-12-17 | — | — | CN | claimed |
| EP-3031800-B1 | PROCESS FOR THE PREPARATION OF HIGH PURITY MIGLUSTAT | NAVINTA LLC (US) | 2019-07-31 | — | — | EP | claimed |
| EP-3404019-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY MIGLUSTAT | Navinta, llc. (US) | 2018-11-21 | — | — | EP | claimed |
| US-9718777-B2 | Process for the preparation of high purity miglustat | NAVINTA, LLC (US) | 2017-08-01 | — | — | US | claimed |
| US-9695111-B2 | Method of producing soluble silicates with organic cations | POLYMATE, LTD. (IL) | 2017-07-04 | — | — | US | claimed |
| US-20170081274-A1 | METHOD OF PRODUCING SOLUBLE SILICATES WITH ORGANIC CATIONS | LIFSCHITZ, YAKOV MARK | 2017-03-23 | — | — | US | claimed |
| US-20160168092-A1 | Process For The Preparation Of High Purity Miglustat | PROVIDENT BANK | 2016-06-16 | — | — | US | claimed |
| EP-3031800-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY MIGLUSTAT | Navinta, llc. (US) | 2016-06-15 | — | — | EP | claimed |
| WO-2006111712-A2 | IONIC LIQUIDS AND USES THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2006-10-26 | — | — | WO | claimed |
| US-6486320-B2 | CONVERGENT SYNTHESIS STARTING FROM A 3-(AMINOMETHYL)QUINOLINE DERIVATIVE AND 5-HYDROXY-5-ETHYL-6-OXO-5,6-DIHYDROPYRANCARBOXYLIC ACID AND THE INTERMEDIATES OBTAINED. | AVENTIS PHARMA S.A. (FR) | 2002-11-26 | — | — | US | claimed |
| US-6316618-B1 | REACTING ETHYL 2-(4-CHLORO-5-FLUORO-2-HALO-3-NITOBENZOYL)-3-((1-HYDROXYPROPY-2(S) -YL)AMINO)ACRYLATE IN PRESENCE OF BASE, REACTING WITH PIPERIDINE COMPOUND, HYDROLYSIS, CYCLIZATION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2001-11-13 | — | — | US | claimed |
| US-5304623-A | Comprising a polyetherurethane, a vinyl polymer having pendant siloxy groups and a partially blocked solid polyisocyanate; adhesives; auto windshields; storage stability | SUNSTAR GIKEN KABUSHIKI KAISHA (JP) | 1994-04-19 | — | — | US | claimed |
| US-4874822-A | REACTING AN ALKENYL AZLACTONE AND A HYDROXYL-CONTAINING COMPOUND OR POLYMER USING A BICYCLE AMIDINE OR TRIVALENT PHOSPHORUS COMPOUND BY PRODUCT INHIBITION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-10-17 | — | — | US | claimed |
| US-4622407-A | Resolution of racemic derivatives of 5-(1-methyl-5-methylthiopyrrol-2-oyl)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-2-carboxylic acid and analogs | MERCK & CO., INC. (US) | 1986-11-11 | — | — | US | claimed |
| US-4608407-A | AMINE SALTS OF PHOSPHORUS-CONTAINING COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-26 | — | — | US | claimed |
| JP-3277620-A | — | — | None | — | — | JP | disclosed |
| US-4594360-A | Compound containing phenyl rings | IOWA STATE UNIVERSITY RESEARCH FOUNDATION & INC. (US) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168092-A1 | Process For The Preparation Of High Purity Miglustat | GANC, GANAB, GAA | L3MBTL3 4585/4885L3MBTL1 4449/4885KDM4E 2175/4885 |
| US-20170081274-A1 | METHOD OF PRODUCING SOLUBLE SILICATES WITH ORGANIC CATIONS | SOST, MTOR, AKT1 | L3MBTL3 2540/4885L3MBTL1 3067/4885KDM4E 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.